Document Classification

Section Type: RESULTS

Text: Mean improvements in papilledema grade (acetazolamide : -1. 31, from 2. 76 to 1. 45 ; placebo : -0. 61, from 2. 76 to 2. 15 ; treatment effect, -0. 70 ; 95 % CI, -0. 99 to -0. 41 ; P <. 001) and vision-related quality of life as measured by the National Eye Institute VFQ-25 (acetazolamide : 8. 33, from 82. 97 to 91. 30 ; placebo : 1. 98, from 82. 97 to 84. 95 ; treatment effect, 6. 35 ; 95 % CI, 2. 22 to 10. 47 ; P =. 003) and its 10-item neuro-ophthalmic supplement (acetazolamide : 9. 82, from 75. 45 to 85. 27 ; placebo : 1. 59, from 75. 45 to 77. 04 ; treatment effect, 8. 23 ; 95 % CI, 3. 89 to 12. 56 ; P <. 001) were also observed with acetazolamide.